Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy
A high-stakes court battle is currently being fought in the US, with the government accusing a big pharma company of patent infringement for the first time.
Gilead Sciences and Kite, a Gilead company, have announced that the National Institute for Health and Care Excellence (NICE) has recommended Yescarta (axicabtagene ciloleucel; axi-cel) for
Although a tone of respectful sobriety lay over the PM Society Awards this year, as the nation’s citizens came from far and wide to London to pay their final respects to Her Majesty Queen Elizabeth
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh